|
1
|
Travis WD, Brambilla E, Muller-Hermelink
HK and Harris CC (eds): World Health Organization Classification of
Tumors, Pathology and Genetics of Tumors of the Lung, Pleura,
Thymus and Heart. 1st edition. IARC Press, Lyon, 2004.
|
|
2
|
Motzer RJ, Amsterdam A, Prieto V,
Sheinfeld J, Murty VV, Mazumdar M, Bosl GJ, Chaganti RS and Reuter
VE: Teratoma with malignant transformation: Diverse malignant
histologies arising in men with germ cell tumors. J Urol.
159:133–138. 1998.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Malagón HD, Valdez AM, Moran CA and Suster
S: Germ cell tumors with sarcomatous components: A
clinicopathologic and immunohistochemical study of 46 cases. Am J
Surg Pathol. 31:1356–1362. 2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Donadio AC, Motzer RJ, Bajorin DF, Kantoff
PW, Sheinfeld J, Houldsworth J, Chaganti RS and Bosl GJ:
Chemotherapy for teratoma with malignant transformation. J Clin
Oncol. 21:4285–4291. 2003.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Marina N, London WB, Frazier AL, Lauer S,
Rescorla F, Cushing B, Malogolowkin MH, Castleberry RP, Womer RB
and Olson T: Prognostic factors in children with extragonadal
malignant germ cell tumors: A pediatric intergroup study. J Clin
Oncol. 24:2544–2548. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Michael H: Somatic neoplasms arising in
germ cell tumors. Pathol Case Rev. 10:181–185. 2005.
|
|
7
|
Mikuz G and Colecchia M: Teratoma with
somatic-type malignant components of the testis. A review and an
update. Virchows Arch. 461:27–32. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Arai K, Ohta S, Suzuki M and Suzuki H:
Primary immature mediastinal teratoma in adulthood. Eur J Surg
Oncol. 23:64–67. 1997.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kesler KA, Rieger KM, Ganjoo KN, Sharma M,
Fineberg NS, Einhorn LH and Brown JW: Primary mediastinal
nonseminomatous germ cell tumors: The influence of postchemotherapy
pathology on long-term survival after surgery. J Thorac Cardiovasc
Surg. 118:692–700. 1999.PubMed/NCBI View Article : Google Scholar
|
|
10
|
GlaxoSmithKline: Votrient Prescribing
Information [cited Jun 1, 2020]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf.
2009.
|
|
11
|
Gril B, Palmieri D, Qian Y, Anwar T, Ileva
L, Bernardo M, Choyke P, Liewehr DJ, Steinberg SM and Steeg PS: The
B-Raf status of tumor cells may be a significant determinant of
both antitumor and anti-angiogenic effects of pazopanib in
xenograft tumor models. PLoS One. 6(e25625)2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kumar R, Knick VB, Rudolph SK, Johnson JH,
Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE,
Onori JA, et al: Pharmacokinetic-pharmacodynamic correlation from
mouse to human with pazopanib, a multikinase angiogenesis inhibitor
with potent antitumor and antiangiogenic activity. Mol Cancer Ther.
6:2012–2021. 2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
van der Graaf WT, Blay JY, Chawla SP, Kim
DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP,
Beppu Y, et al: Pazopanib for metastatic soft tissue sarcoma
(PALETTE): A randomised, double-blind, placebo-controlled phase 3
trial. Lancet. 379:1879–1886. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yoon SS, Segal NH, Park PJ, Detwiller KY,
Fernando NT, Ryeom SW, Brennan MF and Singer S: Angiogenic profile
of soft tissue sarcomas based on analysis of circulating factors
and microarray gene expression. J Surg Res. 135:282–290.
2006.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Necchi A, Lo Vullo S, Giannatempo P, Raggi
D, Calareso G, Togliardi E, Crippa F, Pennati M, Zaffaroni N,
Perrone F, et al: Pazopanib in advanced germ cell tumors after
chemotherapy failure: Results of the open-label, single-arm, phase
2 Pazotest trial. Ann Oncol. 28:1346–1351. 2017.PubMed/NCBI View Article : Google Scholar
|
